Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Axcella Health Inc (AXLA)

Axcella Health Inc (AXLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Axcella Reports First Quarter Financial Results and Provides Business Update

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 0.4009 (-8.89%)
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 0.4009 (-8.89%)
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Pre-Market Brief: Stocks Mixed As Focus Shifts to Big Tech Earnings

March S&P 500 futures (ESH23) are trending down -0.22% this morning after three major U.S. benchmark indices ended the regular session sharply higher as hopes of a less aggressive Federal Reserve boosted...

ESH23 : 3,957.05s (-0.09%)
QCOM : 159.83 (+2.15%)
AMD : 130.15 (+1.89%)
WDC : 69.90 (+1.57%)
CRM : 354.85 (+1.73%)
MSFT : 448.99 (+1.28%)
RHM.D.DX : 619.800 (+2.31%)
AXLA : 0.4009 (-8.89%)
VERB : 8.18 (+11.29%)
PFLT : 11.00 (-0.45%)
ZION : 58.81 (+0.67%)
PTON : 9.79 (+3.05%)
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 0.4009 (-8.89%)
Axcella Announces Program Reprioritization and Corporate Restructuring

Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announces...

AXLA : 0.4009 (-8.89%)
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Axcella Reports Third Quarter Financial Results and Provides Business Update

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)

Barchart Exclusives

These 2 Dividend Stocks Were Stars in November. Is It Too Late to Buy?
These high-yield dividend stocks have posted great returns in 2024 and could keep heating up in the new year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar